Quantumzyme Corp. (OTC: QTZM) announced the publication of its patent titled “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen” by the United States Patent and Trademark Office (USPTO) under publication number US20250146029A1. This milestone validates the company's approach to using computational enzyme engineering for sustainable pharmaceutical production.
The patent details a novel enzymatic process that replaces traditional chemical synthesis with a cleaner, more efficient method. By using a modified polypeptide, the process reduces reliance on harsh chemical reagents, minimizes reaction steps, and improves yield, positioning it as a future-ready solution for Active Pharmaceutical Ingredient (API) production. This innovation aligns with the growing demand for green chemistry in the pharmaceutical industry.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated, "The publication of this patent is a major validation of our scientific approach and commitment to sustainable innovation. It opens new doors for licensing, partnerships, and industry-wide adoption of enzyme-driven manufacturing." The company’s enzymatic process integrates quantum mechanics, molecular modeling, and AI-driven simulations to design high-performance biocatalysts.
This ibuprofen patent adds to Quantumzyme’s growing intellectual property portfolio and strengthens its leadership in enzyme-based solutions for pharmaceuticals, fragrances, food, and specialty chemicals. For more information, visit the company’s website at www.quantumzymecorp.com and its profile at www.otcmarkets.com/stock/QTZM.
